Xcout Intel
OverT Bio, Inc. competitors & alternatives
The 12 closest competitors and alternatives to OverT Bio, Inc. among biotechnology companies — ranked by similarity to what OverT Bio, Inc. actually does, not by market-cap band.
Subscribe to see OverT Bio, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About OverT Bio, Inc.
OverT Bio, Inc. is a New York-based biotechnology company that pioneers next-generation cellular therapies and biologics at scale. The company focuses on developing effective and safe cellular treatments for solid tumors.
OverT Bio, Inc. at a glance
OverT Bio, Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Seed, raised $120,000 in November 2024. Xcout tracks 3 named people at OverT Bio, Inc., including Mat Legut (Co-Founder and CEO).
OverT Bio, Inc. leadership
- Mat LegutCo-Founder and CEO
- Neville SanjanaCo-Founder
- Sara ChoiDirector
OverT Bio, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $120,000 | 9 named | |
| Seed | $16M | 1 named | |
| SEC Form D filing | $16M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 OverT Bio, Inc. competitors
Ranked by semantic similarity — how close each company is to OverT Bio, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Pan Cancer T develops pioneering T-cell receptor (TCR-T) cell therapies designed to empower patients' immune systems to target and overcome solid tumors. The company utilizes proprietary gene engineering to enhance T-cell fitness and persistence against unique cancer-specific intracellular targets.
Similar biotechnology company
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
Similar biotechnology company
ImmuXell Biotechnology is a clinical-stage biopharmaceutical innovation company headquartered in Shanghai, China. Founded in 2021, the company focuses on developing novel immune cell therapies targeted at treating solid tumor cancers.
Similar biotechnology company
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Biotech
Orca Bio is a late-stage biotechnology company developing high-precision cell therapies. These therapies are designed for the treatment of cancer and autoimmune diseases, with a facility located in Sacramento.
Similar biotechnology company
Founded in 2018 and headquartered in San Diego, IconOVir Bio, Inc. is a preclinical-stage biotechnology company that specializes in creating therapies to target cancer cells using engineered viruses.
Biotech
Oxford BioTherapeutics is a clinical-stage oncology company focused on developing first-in-class cancer therapeutics with a proprietary pipeline. The company operates from locations in Oxford, United Kingdom, as well as San Jose, California, and Morristown, New Jersey, in the United States.
Similar biotechnology company
KiraGen Bio is a Boston-based biotechnology company pioneering the development of AI-driven, multiplex gene-edited CAR-T cell therapies designed to target and block tumor suppression.
Biotech
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
Similar biotechnology company
Bakx Therapeutics, Inc. is a private biotechnology company founded in 2020 and based in New York, United States. The company specializes in pre-clinical oncology drug pipelines and novel therapeutics discovery.
Similar biotechnology company
Outpace Bio, Inc. is a biotechnology company headquartered in Seattle, Washington, specializing in AI-powered protein design to advance cell therapies.
Biotech
Tessa Therapeutics is a clinical-stage biotechnology company with its global headquarters in Singapore. The company focuses on developing next-generation cell therapies for cancer and opened a commercial-scale cell therapy manufacturing facility in Singapore in 2020.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of OverT Bio, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for OverT Bio, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →